Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 21 - Drugs for disorders of the muscular or neuromuscular system
Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
12/2002
12/27/2002CA2782791A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2782761A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2782628A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2782623A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2782615A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2782521A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
12/27/2002CA2782519A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
12/27/2002CA2782517A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
12/27/2002CA2782515A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2782494A1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/27/2002CA2450936A1 Purine inhibitors of phosphodiesterase (pde) 7
12/27/2002CA2450934A1 Pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002CA2450809A1 Methods for detecting and treating the early onset of aging-related conditions
12/27/2002CA2450724A1 Quinazoline and pyrido¬2,3-d|pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002CA2450074A1 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage
12/27/2002CA2450067A1 Proteins associated with cell growth, differentiation, and death
12/27/2002CA2430627A1 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
12/26/2002US20020198261 Liquid pharmaceutical compositions
12/26/2002US20020198253 Melatonin derivatives and medicine containing same
12/26/2002US20020198236 Small organic molecule regulators of cell proliferation
12/26/2002US20020198219 2-pyridinamine compositions and related methods
12/26/2002US20020198187 Method of treating sexual disturbances
12/26/2002US20020198179 An estrogen or prodrug micture for reducing or eliminating the incidence of hot flashes and menopausal symptoms, while decreasing the risk of acquiring breast or endometrial cancer, inhibiting the development of osteoporosis
12/26/2002US20020198143 B7-like polynucleotides, polypeptides, and antibodies
12/25/2002CN1387576A Sequence-specific DNA recombination in ekaryotic cells
12/25/2002CN1387575A Method for transfer of molecular substances with prokaryontic nucleic acid-binding proteins
12/25/2002CN1387538A Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
12/25/2002CN1387537A Pharmaceutical compositions and methods of using secreted frizzled related protein
12/25/2002CN1387528A Heterocyclic substd, pyrazolones
12/24/2002US6498275 Use of compounds for the elevation of pyruvate dehydrogenase activity
12/24/2002US6498177 Alpha 2 adrenergic receptor agonist; analgesic, sedative and anaesthetic agents
12/24/2002US6498148 Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a Th1 phenotype
12/19/2002WO2002100859A1 Pde iv inhibitors
12/19/2002WO2002100849A2 Novel nitriles useful as reversible inhibitors of cysteine proteases
12/19/2002WO2002100824A1 A novel alkaloid derivative and a pharmaceutical composition containing the same
12/19/2002WO2002100405A1 Isoquinoline inhibitors of p38
12/19/2002WO2002069899A3 Methods and compositions for the treatment and prevention of smooth muscle cell proliferation
12/19/2002WO2002064755A3 Post-partum mammalian placenta, its use and placental stem cells therefrom
12/19/2002WO2002060894A3 Sulfonamide lactam inhibitors of factor xa
12/19/2002WO2002059080A3 Trisubstituted carbocyclic cyclophilin binding compounds and their use
12/19/2002WO2002058626A9 Methods and compositions for the identification and treatment of neurodegenerative disorders
12/19/2002WO2002055501A3 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them
12/19/2002WO2001072977A9 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
12/19/2002US20020193612 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
12/19/2002US20020193446 Compounds and methods for the inhibition of the expression of VCAM-1
12/19/2002US20020193439 90-95% eicosapentaenoic acid (EPA) and < 5% of docosahexaenoic acid (DHA); treating psychiatric or central nervous disorders
12/19/2002US20020193420 Neurotrophic, low molecular weight, small molecule heterocyclic ketone or thioester compounds are nonimmunosuppressive, has an affinity for FKBP type immunophilins
12/19/2002US20020193317 Using smilagenin, prazerigenin, an astragaloside, tigogenin, ruscogenin, hecogenin and diosgenin in manufacture of medicament for therayp of condition characterised by deficiency in postsynaptic membrane-bound receptor number
12/19/2002US20020192749 Human polynucleotides, polypeptides, and antibodies
12/19/2002US20020192710 Diagnostics, assay methods and amelioration of muscular dystrophy symptoms
12/19/2002US20020192240 Therapy for injured muscles
12/19/2002US20020192216 Therapeutic use
12/18/2002EP1266014A2 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
12/18/2002EP1266012A2 Proteases
12/18/2002EP1266001A2 Human transcription factors
12/18/2002EP1266000A1 Chordin-like-2 molecules and uses thereof
12/18/2002EP1265995A2 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
12/18/2002EP1265919A2 G-protein associated molecules
12/18/2002EP1265900A1 1,5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
12/18/2002EP1265865A2 Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
12/18/2002EP1265862A2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
12/18/2002EP1265860A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
12/18/2002EP1265859A2 Amidino compounds useful as nitric oxide synthase inhibitors
12/18/2002EP1265840A2 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
12/18/2002EP1265616A2 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate
12/18/2002EP1265603A2 Il-8 receptor antagonists
12/18/2002EP0630255B1 Mhc conjugates useful in ameliorating autoimmunity
12/18/2002CN1385175A Medicine for treating dermatomyositis
12/17/2002US6495605 Pure isomers
12/17/2002US6495565 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition
12/17/2002US6495544 Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase
12/17/2002US6495128 Human chemokine β-7 deletion and substitution proteins
12/17/2002CA2260311C Remedy for cag repeat expansion diseases
12/12/2002WO2002099115A2 Nucleic acid-associated proteins
12/12/2002WO2002098880A1 5-ethyl-imidazotriazinones
12/12/2002WO2002098873A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/12/2002WO2002098857A1 New indole derivatives with 5-ht6 receptor affinity
12/12/2002WO2002098850A2 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
12/12/2002WO2002098406A1 Novel compounds and compositions as cathepsin inhibitors
12/12/2002WO2002098346A2 Method and pharmaceutical composition for the treatment of multiple sclerosis
12/12/2002WO2002098226A1 Method for reducing muscle fatigue through administration of adenosine triphosphate
12/12/2002WO2002081398A3 Additives for building industry obtained from by-products and process for their production
12/12/2002WO2002068015A9 Modular infusion device and method
12/12/2002WO2002064080A3 Matrix metalloproteinase inhibitors
12/12/2002WO2002062792A9 Jnk inhibitor
12/12/2002WO2002058620A3 Pharmaceutical compositions containing a cox-ii inhibitor and a muscle relaxant
12/12/2002WO2001097786A3 Benzothiazole derivatives
12/12/2002WO2001089568A9 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
12/12/2002US20020188128 Substituted imidazo[1,2-A] pyridine derivatives
12/12/2002US20020188122 Such as pyridine-4-carboxaldehyde-(4-Morpholinylprop-3-yl) imine for use in therapy as cytokine inhibitors
12/12/2002US20020188118 Compounds and methods for the inhibition of the expression of VCAM-1
12/12/2002US20020188016 Heterocycle derivatives and methods of use
12/12/2002US20020188000 Imidazo-pyridine derivatives as ligands for gaba receptors
12/12/2002CA2449712A1 Method for reducing muscle fatigue through administration of adenosine triphosphate
12/12/2002CA2449109A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/12/2002CA2449097A1 5-ethyl-imidazotriazinones
12/12/2002CA2449021A1 Novel compounds and compositions as cathepsin inhibitors
12/12/2002CA2448606A1 Nucleic acid-associated proteins
12/12/2002CA2448418A1 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
12/12/2002CA2447935A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
1 ... 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 ... 233